Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
8-Jun-2023
Launch of LUMOS2 Study
7-Jun-2023
Constitution
5-Jun-2023
Appointment of Non-executive Director
26-May-2023
Kazia CEO participates in White House Cancer Moonshot Forum
25-May-2023
Cancel - Notification of cessation of securities - KZA
8-May-2023
Notification regarding unquoted securities - KZA
5-May-2023
Notification of cessation of securities - KZA
2-May-2023
Final Director's Interest Notice - Dr J Garner
1-May-2023
Executive Leadership changes - Dr John Friend appointed CEO
28-Apr-2023
Quarterly Activities/Appendix 4C Cash Flow Report
Previous
1
2
3
4
5
6
7
8
9
Next
